January 2018 – The Chief Prosecutor Eleni Touloupaki of the Prosecution office – Corruption Unit of Greece, Ministry of Justice is informed by FBI about the Novartis bribery Scheme to the Greek Government officials. Supportary to the Novartis bribery Scheme to the Greek Government officials FBI provided a full report of their findings involving many Greek Government officials and others.
Novartis Greece and the ones involved in the bribery Scheme including the Greek Government officials until 2024 it is unclear what will happened, as many Greek Government officials especially the Politicians in Greece are “unteachable” despite all the money paid in Bribes by Novartis.
Justice on Novartis’ Greek bribery scheme delivered In USA by the United States Department of Justice
NEWARK, N.J, Thursday, June 25, 2020. – Switzerland-based global pharmaceutical company Novartis AG and a current and former subsidiary will pay $345 million in criminal and regulatory penalties to resolve violations of the Foreign Corrupt Practices Act (FCPA), U.S. Attorney Craig Carpenito, Assistant Attorney General Brian A. Benczkowski of the Justice Department’s Criminal Division, and FBI Acting Special Agent in Charge Douglas Korneski, Newark Field Office, announced today. Novartis Hellas S.A.C.I. (Novartis Greece), a subsidiary of Novartis AG, and Alcon Pte Ltd, a former subsidiary of Novartis AG and current subsidiary of Alcon Inc., a multinational eye care company, have agreed to pay $233 million in criminal penalties to resolve the Department’s investigation into FCPA violations. The resolutions arise out of a Novartis Greece scheme to bribe employees of state-owned and state-controlled hospitals and clinics in Greece and to falsely record improper payments relating to the corrupt scheme and similar conduct, and an Alcon Pte Ltd scheme to make and falsely record improper payments in Vietnam. Novartis AG has also agreed to pay $112 million to the U.S. Securities and Exchange Commission (SEC) in a related matter.
Novartis Greece entered into a deferred prosecution agreement with the Criminal Division’s Fraud Section and the U.S. Attorney’s Office for the District of New Jersey in connection with a criminal information filed today in the District of New Jersey charging Novartis Greece with one count of conspiracy to violate the anti-bribery provisions of the FCPA and one count of conspiracy to violate the books and records provision of the FCPA. Pursuant to the deferred prosecution agreement, Novartis Greece has committed to pay a criminal penalty of $225 million.
fbi sandoz